ORYZON to present new preclinical data of ORY-2001 at the Neuroscience 2017 meeting organized by the Society for Neuroscience

13 November 2017 MADRID, SPAIN and CAMBRIDGE MA. • ORY-2001 reduces aggression in animal models • The drug also reduces social withdrawal • ORY-2001 proposed to restore cognitive function and treat behavioral alterations frequently associated with Alzheimer’s disease patients Oryzon Genomics (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, has presented today new preclinical data on its investigational drug ORY-2001, a selective LSD1-MAOB dual inhibitor, at the SfN’s 47th annual meeting (Neuroscience 2017), being held at the Walter E. Washington Convention Center, Washington DC (USA) in November 11-15. The communication, presented as Poster nº 336.09 at the “Cortical Systems and Mechanisms of Disease” Session and entitled “ORY-2001, a dual LSD1/MAOB inhibitor in development for neurodegenerative diseases, normalizes aggressive behavior in SAMP-8 mice and social avoidance in isolated rats” was presented by neuroscientists from the company accompanied by the Medical Director, Dr. Roger Bullock. Click here to see the full Press Release

The release as fetched from its publisher. oryzon.com ↗